Could fewer HPV vaccine doses offer lasting protection?
NCT ID NCT07706673
First seen Jul 16, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study follows women who previously received either one or two doses of the Gardasil9 HPV vaccine to see how long protection against HPV infection lasts. Researchers will check for persistent infections with HPV types linked to cancer. The goal is to understand if fewer doses still provide strong, long-term immunity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HPV vaccine (Gardasil9)
- What this could lead to
- If successful, this could show that one or two doses of the HPV vaccine provide long-lasting protection, potentially simplifying vaccination schedules and increasing global access.
- What could go wrong
- This is an observational follow-up, not a new treatment test. Protection may wane over time, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-RELATED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, 50101, Costa Rica
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.